Results 81 to 90 of about 1,612,376 (366)

Influenza and memory T cells : how to awake the force [PDF]

open access: yes, 2016
Annual influenza vaccination is an effective way to prevent human influenza. Current vaccines are mainly focused on eliciting a strain-matched humoral immune response, requiring yearly updates, and do not provide protection for all vaccinated individuals.
Glezen   +12 more
core   +3 more sources

The temporal trends and short‐ and long‐term mortality of people with acute myocardial infarction and rheumatoid arthritis: a nationwide cohort study

open access: yesArthritis Care &Research, Accepted Article.
Aims We investigated whether a diagnosis of rheumatoid arthritis (RA) affects the quality of inpatient acute myocardial infarction (AMI) care and long‐term mortality post‐AMI. Methods We analysed data from 784,091 adults, 6,047 with a diagnosis of RA, from England and Wales hospitalised with AMI between 2005 and 2019 from the MINAP registry, linked ...
Megan Butler   +8 more
wiley   +1 more source

T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine

open access: yesViruses, 2021
Current flu vaccines rely on the induction of strain-specific neutralizing antibodies, which leaves the population vulnerable to drifted seasonal or newly emerged pandemic strains.
Anna-Maria Schmidt, D. Lapuente
semanticscholar   +1 more source

Universal flu vaccine? [PDF]

open access: yesNature Reviews Microbiology, 2013
A new study finds that targeting core influenza proteins using virus-specific CD8+ T cells could provide a universal flu vaccine.
openaire   +1 more source

Vaccine strategy when the smallpox model fails: 1. immune cognition, Malaria and the Fulani [PDF]

open access: yes, 2001
We begin to examine the implications of IR Cohen's work on immune cognition [1-3] for vaccine strategies when simple elicitation of sterilizing immunity fails, as is the case for HIV, tuberculosis, and malaria.
Wallace, Robert G, Wallace, Rodrick
core  

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

open access: yes, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source

Setting priorities for development of emerging interventions against childhood diarrhoea [PDF]

open access: yes, 2013
An expert panel exercise was conducted to assess feasibility and potential effectiveness of 10 emerging health interventions against childhood diarrhoea. Twelve international experts were invited to take part in a CHNRI priority setting process.
Bhutta   +18 more
core   +1 more source

Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site‐Specific Integration of CFTR and Mutation‐Agnostic Disease Rescue

open access: yesAdvanced Functional Materials, EarlyView.
Lipid nanoparticles (LNPs) are optimized to co‐deliver Cas9‐encoding messenger RNA (mRNA), a single guide RNA (sgRNA) targeting the endogenous cystic fibrosis transmembrane conductance regulator (CFTR) gene, and homologous linear double‐stranded donor DNA (ldsDNA) templates encoding CFTR.
Ruth A. Foley   +12 more
wiley   +1 more source

Promising strategy for developing mRNA-based universal influenza virus vaccine for human population, poultry, and pigs– focus on the bigger picture

open access: yesFrontiers in Immunology, 2022
Since the first outbreak in the 19th century influenza virus has remained emergent owing to the huge pandemic potential. Only the pandemic of 1918 caused more deaths than any war in world history.
Nino Rcheulishvili   +5 more
doaj   +1 more source

Neonatal vaccination with 'universal strength' BCG vaccine. [PDF]

open access: yesArchives of Disease in Childhood, 1977
'Universal strength' BCG vaccine was given to 219 neonates and 2 months later 159 infants were Mantoux-tested with 5 Tu PPD-S and their BCG scars measured. The results showed a satisfactory conversion rate of over 90%. Though 30% of the lesions discharged, this only lasted for a few days and the vaccine was well tolerated and acceptable for use in ...
B, Heyworth, B M, Mullinger
openaire   +2 more sources

Home - About - Disclaimer - Privacy